

Email Contact: whillegass@uabmc.edu

William B. Hillegass, M.D., Ph.D.

EDUCATION

- 8/08 – 8/17. School of Public Health, University of Alabama at Birmingham, Department of Biostatistics, Ph.D., Biostatistics.
- 9/83 - 6/88. Harvard Medical School, Boston, MA. Doctor of Medicine. *magna cum laude*.
- 9/86 - 6/88. Harvard School of Public Health, Boston, MA. Master of Public Health. Health services administration and management, outcomes research.
- 8/79 - 5/83. Yale University, New Haven, CT. B.A., Molecular Biophysics and Biochemistry. B.A., Economics and Political Science. *magna cum laude*.
- 8/75 - 5/79. Marysville High School, Marysville, OH. Valedictorian.

EMPLOYMENT/RESEARCH/TRAINING

- 4/17 – present. Attending Cardiologist, Associate Professor of Cardiovascular Medicine and Assistant Professor of Biostatistics, Cardiovascular Division and Department of Biostatistics, University of Alabama at Birmingham.
- Clinical duties: general and invasive cardiovascular medicine.
 - Research: clinical and pre-clinical research on coronary, cerebral, and peripheral vascular diseases/project statistician/basic statistical methods research and development.
 - Teaching: patient care, statistics in medicine.
- 2/11 – 3/17. Cardiologist, Heart South Cardiovascular Group, P.C., Alabaster, Alabama. General and interventional cardiovascular practice and research.
- 2/11 – 2/17. Columbiana Cardiovascular Research Consulting, LLC, Columbiana, AL
- Cardiovascular research.
 - Cardiovascular economic, outcomes, and statistical research and consultation services.
 - Cardiovascular continuing medical education programs and materials.
 - Independent cardiovascular care quality and appropriateness assessment.
 - Cardiovascular outcomes and appropriateness prediction modeling, database, and software development.
 - Probabilistic medical decision modeling and standard of care modeling. Cardiovascular consulting with probabilistic evaluation of care strategies utilized.
- 8/11 – 9/13. Attending Interventional Cardiologist, Cardiovascular Division, University of Alabama at Birmingham.
- Clinical duties: invasive/interventional cardiovascular medicine.
 - Research and research mentor: clinical and pre-clinical research on coronary, cerebral, and peripheral vascular diseases.
 - Teaching: procedural teaching in catheterization laboratories and associated patient care.
- 7/11- 6/13. T32 Fellow in Health Services Research and Comparative Effectiveness Research, Center for Outcomes and Effectiveness Research and Education (COERE), University of Alabama at Birmingham

- '05 – 1/11
'00 – 05 Associate Professor of Medicine, Cardiovascular Division, University of Alabama at Birmingham.
Assistant Professor of Medicine, Cardiovascular Division, University of Alabama at Birmingham.
- Clinical duties: general/invasive/interventional cardiovascular medicine.
 - Research and research mentor: clinical and pre-clinical research on coronary, cerebral, and peripheral vascular diseases.
 - Teaching: Director, Interventional Cardiovascular Fellowship Program, 1/03 to 6/09. Further developed interventional fellowship program including creation of curriculum, weekly teaching conferences, evaluation processes, obtained ACGME initial accreditation and reaccreditation as well as program funding. Created dedicated interventional cardiovascular research fellowship program including funding.
- '99 – 00 Cardiologist, The Heart Group. Medical Director, Peripheral Vascular Disease Program, Heartcare Health System, Evansville, IN.
- Clinical duties: general/invasive/interventional cardiovascular medicine
 - Developed peripheral vascular program including noninvasive studies, patient screening, angiography, intervention, and research.
- '95 – 99. Assistant Professor of Medicine, Division of Cardiology, Vanderbilt University Medical Center, and Nashville Veteran's Administration Medical Center, Nashville, TN. Director of Cardiovascular Database and Peripheral Revascularization Program in Cardiology.
- Clinical duties: general cardiology practice, CCU attending, invasive/interventional cardiovascular care.
 - Outreach: helped develop and staff two satellite practices and create affiliation with an independent cardiology practice.
 - Database: directed development of a catheterization laboratory database system and software package for management, quality-assurance, and research.
 - Peripheral Revascularization Program: developed peripheral vascular disease program in cardiology to evaluate, manage, and teach PVD. Experience includes lower extremity, renal, brachiocephalic, and carotid evaluation and intervention.
- '91 - 94. General and Interventional Cardiovascular Fellow, Divisions of Cardiology and Cardiovascular Databank, Duke University Medical Center, Durham, NC. General cardiology, invasive and interventional cardiac and peripheral vascular sub-specialty training.
- '88 - 90. Resident Physician, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
- '87 - 90. Research Assistant, Divisions of Cardiology and Clinical Epidemiology, Brigham and Women's Hospital, Boston, MA. Supervisors: Drs. James E. Muller, Thomas Lee, and Lee Goldman.
- 6/84 - 8/84. Research Assistant, Robert Wood Johnson Foundation Program for Hospital Initiatives in Long-term Care, Mass. Gen. Hospital, Boston, MA. Supervisor: Alan Jette, Ph.D.
- 6/83 - 8/83. Research Assistant, Yale Medical School, New Haven, CT. Supervisor: William Summers, M.D., Ph.D., Professor of Biochemistry.
- 9/82 - 5/83. Research Assistant, Yale University, New Haven, CT. Supervisor: Paul Howard-Flanders, Ph.D., Professor of Molecular Biology.
- 5/82 - 8/82. Policy Intern, North Carolina Board of Science and Technology, Office of the Governor, Raleigh, NC.

- 5/81 - 8/81. Legislative Intern. National Consumers League, Washington, D.C.
- 5/80 - 8/80. Congressional Intern, Congressman Clarence J. Brown (7th Ohio), Washington, D.C.

Certifications and Licenses

Alabama MD License 2000
 Fellow, American College of Cardiology 2000
 Fellow, Society of Vascular Medicine and Biology 2006
 Fellow, Society of Cardiovascular Angiography and Intervention 2008
 Board Certified, Vascular Medicine, American Board of Vascular Medicine 2006
 Board Certified, Endovascular Medicine, American Board of Vascular Medicine 2006
 Board Certified, Interventional Cardiovascular Medicine 2000, Recertified 2011
 Board Certified, Cardiovascular Medicine 1995, Recertified 2002 & 2012
 Board Certified, Internal Medicine 1992, Recertified 2002 & 2011
 Diplomate. National Board of Medical Examiners 1988
 Specific Device Certification
 Directional Atherectomy 7/28/94
 Palmaz-Schatz (J&J) Stents 4/10/95
 Gianturco-Roubin (Cook) Stents 1/27/95
 Rotational Atherectomy 6/13/95
 Transluminal Extraction Catheter 10/5/97
 Perclose 10/99
 Cutting Balloon 1/10/01
 Excimer Coronary and Peripheral Vascular Laser 2/02
 Galileo III Brachytherapy System (Guidant) 4/11/03
 FilterWire 11/20/03

Procedural Experience (as of 4/30/2016)

left heart catheterization	6495
right heart catheterization	2366
coronary interventional	3877
IABP/Impella/Tandem Heart	335
biopsy	770
peripheral and neurovascular diagnostic	1416
peripheral and neurovascular interventional	617
intravascular ultrasound	136
pericardiocentesis	62
catheter directed thrombolysis/EKOS	78

Journal Reviewer

American Heart Journal
 American Journal of Cardiology
 BioMed Central Health Services Research
 Cardiovascular Catheterization and Intervention
 Circulation
 Clinical Epidemiology
 American College of Physicians Journal Club
 Journal of the American College of Cardiology
 Journal of the American College of Cardiology Intervention
 Journal of Critical Illness
 PharmacoEconomics
 Journal of the American Medical Association

Statistical Reviewer

Cardiovascular Catheterization and Intervention
Circulation: Cardiovascular Outcomes and Quality
Journal of the American Medical Association
Journal of the American Medical Association – Cardiology
(portfolio of recent reviews available upon request)

Biostatistics PhD Program

Courses Completed in MS/PhD Program:

Statistical Methods I
Statistical Methods II
General Linear Models
Data Management and Reporting with SAS
Statistical Theory I
Statistical Theory II
Advanced Problems in Statistical Theory
Categorical Data Analysis
Survival Analysis
Applied Multivariate Analysis
Theory of Linear Models
Advanced Inference (Large sample theory)
Generalized Linear and Mixed Models
Advanced Computational Methods (using R)
Principles of Epidemiologic Research
Design and Conduct of Clinical Trials
Advanced Clinical Trials I
Advanced Clinical Trials II
Statistical Consulting
Meta-Analysis
Analysis of Case-Control Studies
Cost-Effectiveness Research Methods
Non-parametric Statistical Methods
Qualitative and Mixed Methods
Introduction to Computer Science and Programming
Computational Science and Engineering I

Qualifying Exams: Passed statistical theory and applied statistical qualifying exams.

Dissertation: Novel Methods for Adjusted Indirect Trial Comparisons, advisor Gary Cutter, PhD.

Other Methodological Research:

Methods for Meta-Regression of Adjusted Observational Studies
Weighted Concordance Index for Assessment of Risk Prediction Model Performance

Programming Experience with research projects application experience:

SAS
R
SPSS

Programming Knowledge without research project application experience so far:

SQL
Python

Abstract Grader

American Heart Association

2007 - 2010

American College of Cardiology	2007 - 2010
Society of Cardiovascular Angiography and Intervention	2009 – 2010
American College of Cardiology Alabama Chapter	2014 - 2015

Editorial Board

Cardiovascular Catheterization and Intervention

Memberships

Fellow American College of Cardiology
 Fellow Society of Vascular Medicine and Biology
 Fellow Society of Cardiac Angiography and Intervention

Scientific Session Chair

American Heart Association 2007

Training Grants Obtained for Interventional Cardiovascular Fellowship Program 2003 to 2008: \$814,000

2008	\$45,000	Abbott Foundation
	\$60,000	Society of Cardiac Angiography and Intervention
2007	\$50,000	Guidant Foundation
	\$75,000	Cordis Foundation
	\$75,000	Boston Scientific Foundation
2006	\$50,000	Guidant Foundation
	\$100,000	Cordis Foundation
	\$75,000	Boston Scientific Foundation
2005	\$50,000	Guidant Foundation
	\$75,000	Cordis Foundation
	\$75,000	Boston Scientific Foundation

Research

Single Center Studies (total funding support: \$1,340,000)

- Hyperglycemia and contrast-induced nephropathy. Principal Investigator.
- Effectiveness of methods for left ventriculography. Principal Investigator.
- Prophylactic statin therapy in SVG PCI. Principal Investigator.
- N-Acetylcysteine for Contrast Nephropathy Prevention in 829 Patients with Chronic Renal Insufficiency. Principal Investigator.
- Sirolimus Drug-Eluting Stenting for Allograft Arteriopathy. Principal Investigator. Support: Cordis
- Nitric oxide donor prophylaxis in SVG PCI. Principal Investigator.
- Effect of ABCIXIMAB On Clinical Outcomes, Functional Health Status, and Economic Impact in Percutaneous Coronary Intervention. Principal Investigator. Support: Lilly.
- GENECARD - Genetics Studies of CAD. Sibling pair study to identify genetic markers for premature CAD. Site Co-Principal Investigator. Support: Glaxo-Wellcome.
- Heparin Coated Stent Outcomes in 1,000 Consecutive Patients. Principal Investigator. Support: Johnson&Johnson

Multicenter Studies & Registry Participation (as site PI)

(total funding support: \$7,300,000)

Completed Include:

CRISP-AMI Local Principal Investigator: William B. Hillegass, MD
Maquet, Inc.
Prophylactic IABP in primary PCO of anterior STEMI to reduce reperfusion injury.

SPIDER Clinical Trial Local Principal Investigator: William B. Hillegass, MD
EV3, Inc.
Novel distal protection filter device during coronary intervention.

X-TRACTION Clinical Trial Local Principal Investigator: William B. Hillegass, MD
EV3, Inc.
Experimental thromboatherectomy device for coronary vein graft intervention.

VALOR – contrast nephropathy. 2003-2004. Site Principal Investigator. Support: Amersham/GE Healthcare.

PREFER – ABT-578 Coated BiodivYsio Stent. 2003. Site Principal Investigator. Support: Abbott Vascular Devices.

LOGIC – Logic stent vs. approved stent. 2001-2003. Site Principal Investigator. Support: Cook, Inc.

LP STENT- Low pressure stent deployment design. 2000-2002. Site Principal Investigator. Support: IVT, Inc.

PRESTO – Phase III, Prevention of Restenosis with Tranilast and Its Outcomes: A Placebo-Controlled Trial. 1999-2000. Site Principal Investigator. Support: SmithKline Beecham.

TRAFFIC – Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Recombinant Fibroblast Growth Factor-2 in Subjects with Stable Intermittent Claudication due to Peripheral Vascular Disease. 1999-2000. Site Principal Investigator. Support: Chiron.

PRO-ACS Registry – Acute coronary syndrome evaluation and management registry. Site Principal Investigator and Scientific Advisory Group. 1998-2000. Support: Lilly and Centocor.

TRACs Registry - Acute coronary syndrome evaluation and management registry. 1999-2000. Site Principal Investigator. Support: Merck.

SPEED (GUSTO-IV pilot) - ReoPro with reduced dose rPA in ST-segment elevation acute MI. Site Principal Investigator. 1997-1999. Support: Centocor.

UNIVERSITY HOSPITAL CONSORTIUM – Coronary intervention registry. 1996-1999. Site Principal Investigator.

Other

2017 Frank Hildner Elite Reviewer Award, Cardiovascular Catheterizations and Interventions, Society of Cardiovascular Angiography and Intervention.

2017 Chair, National Cardiovascular Data Registry Pinnacle Registry Limited Data Set Workgroup.

2016-present. National Cardiovascular Data Registry Science and Quality Oversight Committee Data Governance Subcommittee

- 2015 2015 Naomi Fineberg Distinguished New Researcher Award, Department of Biostatistics, University of Alabama at Birmingham.
- 2014 – present. Interventional Cardiovascular Maintenance of Certification Exam beta tester, American Board of Internal Medicine.
- 2011 – present. Pharmacoepidemiology and economics research (PEER) group, participant, multidisciplinary research group at University of Alabama at Birmingham with claims and large database studies.
- 2007 - present America’s Top Doctors Recognition
- 2006 – 2013 Research and Publications Subcommittee, American College of Cardiology -National Cardiovascular Data Registry (ACC-NCDR) CathPCI Registry.
- 7/2011- 6/2013. T32 Fellow in Health Services Research and Comparative Effectiveness Research, Center for Outcomes and Effectiveness Research and Education (COERE), University of Alabama at Birmingham
- 2007- 2011. Ad Hoc Peripheral Vascular Disease Committee, Society for Cardiovascular Angiography and Intervention
- 2006 – 2012. Quality of Life Writing Committee, BARI 2D Trial
- 2005 – 2010. Training Program Standards Committee, Society for Cardiovascular Angiography and Intervention
- 2009 – 2010. American College of Cardiology Foundation/Brookings Project Internal Workgroup – creating a national longitudinal PCI outcomes registry.
- 2009 – 2010. Get Real: Real World PCI Outcomes Registry, steering committee.
- 2009 – 2010. Speaker’s bureau for Faculty Resources (Daichi-Sanyo/Lilly – prasugrel).
- 2007- 2010 American College of Cardiology Live Programs Committee.
- 2006 – 2010. Peripheral Vascular Disease Writing Committee, BARI 2D Trial
- 2005 – 2010. Program Directors’ Committee, Society for Cardiovascular Angiography and Interventions
- 2000 - 2002 SWING – Sound Wave Inhibition of Neointimal Growth. Data and Safety Monitoring Board.
- 1999 - 2000 Peripheral Vascular Disease Advisory Board, Centocor/Johnson&Johnson.
- 1999 - 2000 Continuing Medical Education Speaker’s Program, cilostazol therapy for peripheral vascular disease, Otsuka Pharmaceuticals/Pharmacia&Upjohn.
- 1999 - 2000 Continuing Medical Education Speaker’s program, clopidogrel therapy for peripheral arterial disease, Sanofi/Bristol-Myers Squibb Company.
- 1998 - 2000 Scientific Advisory Group. PRO-ACS. Patient outcomes in acute coronary syndrome registry.
- 1998 – 2001. Peripheral Atherosclerosis Research Consortium, founding member.
- 1995 – 1996 PARADIGM – Lamifiban with thrombolysis in acute MI. Data and Safety Monitoring Board.

- 1992 - 1993 GUSTO hotline physician. GUSTO-1 stroke review group.
- 1992 - 1993 EPIC clinical endpoints review committee.
- 1992 - 1994 Angioplasty Trials Pool (ATP) coordinator. Multicenter pooled database of the CADRES, CAVEAT, PBC, MARCATOR, MHEART, EPIC, CCAT, GRASP, Angiopeptin, and other interventional cardiology trials.
- 1993 Henry Christain Award for Clinical Research, American Federation For Clinical Research.
- 1993 Young Trainee Investigator Award, American Federation of Clinical Research
- 1981-85 Truman Scholar. Harry S. Truman Memorial Foundation.
- 1980 Townsend Prize. Yale University freshman essay contest first prize.

PUBLICATIONS

a) articles

K Winther, **WB Hillegass**, GH Tofler, A Jiminez, DA Brezinski, AI Schafer, J Loscalzo, GH Williams, JE Muller. Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. *Am J Cardiol* 1992;70:1051-1055.

WB Hillegass, EM Ohman. Preventing restenosis: what have we learned? *Choices in Cardiology* 1993;7:164-167.

WB Hillegass, JG Jollis, CB Granger, EM Ohman, RM Califf, DB Mark. Intracranial hemorrhage risk and new thrombolytic therapy in acute myocardial infarction. *Am J Cardiol* 1994; 73:444-449.

WB Hillegass, EM Ohman, JD Leimberger, RM Califf. A meta-analysis of randomized trials of calcium channel blockers to reduce restenosis after coronary angioplasty. *Amer J Cardiol* 1994; 73:835-839.

CR Narins, **WB Hillegass**, CL Nelson, RA Harrington, HR Phillips, RS Stack, RM Califf. Activated clotting time predicts abrupt closure risk during angioplasty. *Circulation* 1996; 93:667-671.

WB Hillegass. The economics of IIb/IIIa therapy. *J Invasive Cardiol* 1996; 8:30-33B.

RM Califf, BE Tardiff, KS Pieper, **WB Hillegass**. The use of calcium channel antagonists in myocardial revascularization procedures. *Amer J Cardiol* 1996; 77(16):26D-31D.

M Agirbasli, **WB Hillegass**, GD Chapman, BC Brott. Stent procedure complicated by thrombus formation distal to the lesion within a muscle bridge. *Catheterization and Cardiovascular Diagnosis* 1997;42:1-4.

AK Goklaney, JD Murphy, **WB Hillegass**. Abciximab therapy in percutaneous intervention: Economic issues in the United States. *Am Heart J* 1998; 135:S90-S97.

JJ Ferguson, DJ Kereiakes, AAJ Adgey, KA Fox, **WB Hillegass**, M Pfisterer, C Vassanelli. Safe use of platelet GP IIb/IIIa inhibitors. *Am Heart J* 1998; 135:S77-S89.

WB Hillegass, AR Newman, DL Raco. Economic issues in glycoprotein IIb/IIIa receptor therapy. *Am Heart J* 1999;136:S24-32.

WB Hillegass, AR Newman, DL Raco. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and acute coronary syndromes: economic implications. *PharmacoEconomics* 2001;19(1): 41-55.

WB Hillegass, NA Dean, L Liao, RG Rhinehart, PR Myers. The treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. *J Am Coll Cardiol* 2001;37:1335-43.

M Singh, GS Reeder, EM Ohman, V Mathew, **WB Hillegass**, RD Anderson, DS Gallup, KN Garratt, DR Holmes. Does the presence of thrombus seen on coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. *J Am Coll Cardiol* 2001; 38(3):624-630.

Robert J. Lederman, Farrell O. Mendelsohn, R. David Anderson, Jorge F. Saucedo, Alan N. Tenaglia, James B. Hermiller, **William B. Hillegass**, Krishna Rocha-Singh, Thomas E. Moon, MJ Whitehouse, and Brian H. Annex for the TRAFFIC investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: the TRAFFIC study. *Lancet* 2002; 359:2053-2058.

WB Hillegass, BC Brott, GD Chapman, HR Phillips, RS Stack, JE Tchong, RM Califf. The relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. *Am Heart J* 2002; 141(3):501-7.

WB Hillegass. How best to use GPIIb/IIIa receptor inhibitors in suspected acute coronary syndromes. *J Crit Illness* 2002;17(12):464-466.

TR Tolleson, JC O'Shea, J Bittl, **WB Hillegass**, KA Williams, G Levine, RA Harrington, JE Tchong. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT Trial. *JACC* 2003;41:386-393.

WB Hillegass, GJ Zoghbi, A Pandey, V. Misra, GD Chapman, MD, BC Brott. Treatment of in-stent restenosis in a gastroepiploic artery coronary bypass graft with brachytherapy. *Journal of Invasive Cardiology* 2003; 15:677-680.

GJ Zoghbi, VK Misra, GD Chapman, **WB Hillegass**, BC Brott, RA Aqel, RC Bourge. Long-term follow-up of brachytherapy for treatment of allograft in-stent restenosis. *Catheterization and Cardiovascular Interventions* 2004;61:217-221.

WB Hillegass, M Goyal, VK Misra, WD Jordan. Cypher drug-eluting stent treatment of tibioperoneal obstructive disease. *Catheterization and Cardiovascular Interventions* 2005;64:237-241.

BC Brott, A Anayiotos, GD Chapman, PG Anderson, **WB Hillegass**. Profound, diffuse, refractory coronary artery spasm after drug-eluting stent placement. *J Invasive Cardiol.* 2006 Dec;18(12):584-92.

WB Hillegass, H Gupta, R Katragadda, J Knoblauch, C Coghlan, VK. Misra. Ruptured giant right coronary artery aneurysm percutaneously plugged: case report and review of the literature. *J Invasive Cardiol.* 2007 Mar;19(3):139-41.

S Rajdev, MK Goyal, **WB Hillegass**, VK Misra. First human use of Tandem Heart assisted high-risk percutaneous aortic valvuloplasty using bivalrudin anticoagulation. *J Invasive Cardiol.* 2007 Jan;19(1):E5-8.

WB Hillegass. DES for saphenous grafts: A treatment in vain? *Catheterization and Cardiovascular Interventions* 2008; 72(1):21-22.

BARI-2D Investigators, . . . , **Hillegass, WB**, et al. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Am Heart J* 2008; 156(3): 528-536.

WB Hillegass. The bone marrow and endovascular therapy. *Catheterization and Cardiovascular Interventions* 2008; 72(2):210-211.

WB Hillegass. Native vessel PCI in the diabetic: DES whenever feasible. *Catheterization and Cardiovascular Interventions* 2008; 72(5):608-609.

SK Koshy, Kleiman NS, George LK, Misra V, **Hillegass WB**, Brott BC. Vascular changes and black hole phenomenon after coronary brachytherapy: a pathologically distinct entity. *J Invasive Cardiol* 2008; 20(10):560-562.

WB Hillegass. CABG versus DES PCI in diabetics with multivessel disease: back to the BARI registry. *Catheterization and Cardiovascular Interventions* 2009; 73(1):59-60.

RH. Mehta, FS Ou, ED Peterson, RE Shaw, **WB Hillegass**, JS Rumsfeld, MT Roe, On Behalf of the American College of Cardiology-National Cardiovascular Database Registry Investigators. Clinical Significance of Thrombolysis In Myocardial Infarction Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. *J American College of Cardiology Intervention* 2009; 2: 56-64.

GJ Zoghbi, MK Goyal, FG Hage, PR Myers, SE Papapietro, BC Brott, VK Misra, AE Iskandrian, **WB Hillegass**. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. *J Invasive Cardiol* 2009;21(2):34-39.

WB Hillegass. A third dimension to uncloud the funnel plot of operator quality. *Catheterization and Cardiovascular Interventions* 2009; 73(5):595-6.

WB Hillegass. Multivessel disease in diabetics: does DES level the field? *Catheterization and Cardiovascular Interventions* 2009; 73(7):881-2.

Hillegass, WB. The modern axis of peri-procedural evil. *Catheterization and Cardiovascular Interventions* 2009; 74(1):56-57.

Xiang DC, **Hillegass WB**, Luo GX, He JX. Treatment of refractory iatrogenic femoral artery pseudoaneurysm with a vascular closure device. *J Vasc Interv Radiol* 2009; 20(12): 1639-40.

Hillegass, WB. Vertebrobasilar intervention: as goes the access, so goes the procedure. *Catheterization and Cardiovascular Interventions* 2009; 74(6):932-3.

Hillegass, WB. Length matters: outcomes of superficial femoral artery (SFA) endovascular interventions. *Catheterization and Cardiovascular Interventions* 2009; 74(7):1096.

Hlatky MA, Chung SC, Esobedo J, **Hillegass WB**, Brooks MM, for the BARI2D Investigators. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. *Amer Heart J* 2010; 159(2):292-300.

Hillegass WB. Bifurcation stenting: a commitment to always kiss. *Catheterization and Cardiovascular Interventions* 2010; 75(4):614-5.

Hillegass, WB. Which DES for diabetics? *Catheterization and Cardiovascular Interventions* 2010; 76(1):58-9.

Hillegass WB Drug-eluting or bare metal stents for diabetics: clinical judgment still wins. *Catheter Cardiovasc Interv*. 2010 Oct 1;76(4):482-3. PMID: 20882648

Hillegass WB. The Holy Grail for DES: does efficacy translate into real world effectiveness? *Catheter Cardiovasc Interv*. 2010 Sep 1;76(3):381-2. PMID: 20839352

Maria Mori Brooks¹, Sheng-Chia Chung¹, Tarek Helmy, **William B Hillegass**, Jorge Escobedo, Kathryn Melsop, Elaine Massaro, Robert McBane, , Pamela Hyde, Mark A. Hlatky and the BARI 2D Study Group Quality of Life after Treatment for Coronary Artery Disease and Type 2 Diabetes in BARI 2D. *Circulation* 2010; 122(17): 1690-9.

Hillegass WB. High glyceic stenting menu. *Catheter Cardiovasc Interv*. 2010 Dec 1;76(7):934-5.

Hillegass WB. DES in SVG disease: safe and at least effective short-term. *Catheter Cardiovasc Interv*. 2011 Feb 15;77(3):356-7.

Hillegass WB. Review: Third-generation P2Y12 inhibitors reduce mortality after PCI more than clopidogrel. *Ann Intern Med*. 2011 Mar 15;154(6):JC3-6. PMID:21403069

Hillegass WB. A full toolbox fixes the roadblocks: the value of pan-endovascular skills. *Catheter Cardiovasc Interv*. 2011 April 1;77(5):759-760. PMID: 21433277

Moliterno DJ et al. ; TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. *Catheter Cardiovasc Interv.* 2011 June 1;77(7):1001-1009. (search PubMed under Hillegass, WB) PMID: 21598351

LW Klein, BF Uretsky, C Chambers, M Singh, KKL Ho, **WB Hillegass**, HV Anderson, SV Rao, J Reilly, BH Weiner, M Kern, S Bailey. Quality Assessment and Improvement in Interventional Cardiology A Position Statement of the Society of Cardiac Angiography & Interventions. Part I. Standards for Quality Assessment & Improvement in Interventional Cardiology *Catheter Cardiovasc Interv.* 2011 June 1;77(7):927-35. PMID: 21370384

WB Hillegass, BC Brott, JC Dobbs, VK Misra, GJ Zoghbi. Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. *Vascular Health and Risk Management* 2011; July 2011 Volume 2011:7 Pages 445 – 459. DOI: <http://dx.doi.org/10.2147/VHRM.S4746> PMID:21822392

LW Klein, KKL Ho, M Singh, BF Uretsky, C Chambers, HV Anderson, **WB Hillegass**, SV Rao, J Reilly, BH Weiner, M Kern, S Bailey. Quality Assessment and Improvement in Interventional Cardiology A Position Statement of the Society of Cardiac Angiography & Interventions. Part II. Optimal Methods to Assess & Improve Interventional Program Quality: Risk Models and Public Reporting. *Catheter Cardiovasc Interv* 2011 Oct 1;78(4):493-502. PMID: 21547998

WB Hillegass. Shock and age: the role of an early invasive strategy. *Catheter Cardiovasc Interv.* 2011 Oct 1;78(4):512-513. PMID: 21953749

WB Hillegass. Diabetes and percutaneous coronary intervention: drug-eluting:stents whenever feasible. *Catheter Cardiovasc Interv.* 2011 Nov 1;78(5):718-719. PMID: 22025471

JM Brennan, D Dai, MR Patel, SV Rao, EJ Armstrong, JC Messenger, JP Curtis, KA Shunk, KJ Anstrom, EL Eisenstein, WS Weintraub, ED Peterson, PS Douglas, **WB Hillegass**. Characteristics and Long-term Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis in the United States: A Report from the National Cardiovascular Data Registry, 2004-2008. *J Am Coll Cardiol*, Volume 59, Issue 7, 14 February 2012, Pages 648-654. PMID: 22322080

WB Hillegass. Implicit rationing of percutaneous coronary intervention: The left main test case. *Catheter Cardiovasc Interv.* 2012 Jun 1;79(7):1117. PMID: 22674763

Brott BC, **Hillegass WB**. Commentary: 24- and 6-month dual antiplatelet therapy aafter coronary stenting did not differ for clinical outcomes. *Ann Intern Med* 2012;157(4):JC2-9. PMID: 22910963

WB Hillegass. Benefit of Renal Artery Stenting: Is On-Target Therapy the Observational Bias? *Catheter Cardiovasc Interv.* 2012 September 1,80(3):351. PMID: 22933345

Hillegass, WB. Rotational Atherectomy for Heavily Calcified Unprotected Left Main Disease: Proceed With Caution. *Catheter Cardiovasc Interv.* 2012 Aug 1;80(2):221. doi: 10.1002/ccd.24525. PMID: 22825985

Hillegass, WB, Patel, MR, Klein LW, Gurm, HS, Brennan, JM, Anstrom, KA, Dai, D, Eisenstein, EL, Peterson, ED, Messenger, JC, Douglas PS. Long-Term Outcomes of Older Diabetic Patients after Percutaneous Coronary Stenting in the United States: a report from the National Cardiovascular Data Registry, 2004-2008. *J Am Coll Cardiol* 2012. 60(22) 2280-9. PMID: 23194940

WB Hillegass, BC Brott. Saphenous Vein Grafts: Two Substrates, Two Treatments? *Catheter Cardiovasc Interv.* 2012;80(7):1137 PMID: 23225651.

Hillegass WB. Diabetes and everolimus-eluting stents. *Catheter Cardiovasc Interv* 2013;81(5):766-7. PMID: 23526617

Hillegass WB. Stent paleology: diabetic lessons from extinct stents. *Catheter Cardiovasc Interv* 2013;81(7):1125-6. PMID: 23704065

Feldman DN¹, Swaminathan RV¹, Kaltenbach L², Baklanov D³, Kim LK¹, Wong SC¹, Minutello RM¹, Messenger JC⁴, Moussa I⁵, Garratt KN⁶, Piana RN⁷, **Hillegass WB**⁸, Cohen MG⁹, Gilchrist IC¹⁰, Rao SV². Adoption of Radial Access and Comparison of Outcomes to Femoral Approach in Percutaneous Coronary Intervention: An Updated Report From the NCDR[®] (2007-2012). *Circulation* 2013; 127:2295-2306.

Hillegass WB, Brott BC. Thromboaspiration and Iib/IIIa therapy in STEMI: Abciximab redux? *Catheter Cardiovasc Interv* 2013;82(4):612-3. PMID: 24078419

Zhang J, Chen L, Delzell E, Muntner P, **Hillegass WB**, Safford MM, Millan IYN, Crowson CS, Curtis JR. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2014 Jul;73(7):1301-8. doi: 10.1136/annrheumdis-2013-204715. Epub 2014 May 5.

Zhang J, Chen L, Delzell E, Muntner P, **Hillegass WB**, Safford MM, Millan IYN, Crowson CS, Curtis JR. **Republished:** The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. *Postgrad Med J.* 2014 Dec;90(1070):722-9. doi: 10.1136/postgradmedj-2013-204715rep.

Hess CN, Peterson ED, Neely ML, Dai D, **Hillegass WB**, Krucoff MW, Kutcher MA, Messenger JC, Pancholy S, Piana R, Rao S. The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry. *Circulation.* 2014 Jun 3;129(22):2277-86. doi: 10.1161/CIRCULATIONAHA.113.006356. Epub 2014 Apr 22.

Hess CN, Peterson ED, Neely ML, Dai D, **Hillegass WB**, Krucoff MW, Kutcher MA, Messenger JC, Pancholy S, Piana RN, Rao SV. Response to letter regarding article, "The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry". *Circulation.* 2015 Feb 24;131(8):e358. doi: 10.1161/CIRCULATIONAHA.114.013278. PMID:25712065

Hillegass WB, Brott BC. Optimal DAPT duration: each in their own time. *Catheter Cardiovasc Interv.* 2015 Jan 1;85(1):41-2. doi: 10.1002/ccd.25737.

Hillegass WB, Brott BC. Can femoral access bleeding outcomes be improved? *Catheter Cardiovasc Interv.* 2015 Feb 15;85(3):380-1. doi: 10.1002/ccd.25808. PMID: 25684716

Hillegass WB, Brott BC. Percutaneous coronary intervention: Ever closer to real world silver bullets!? *Catheter Cardiovasc Interv.* 2015 Apr;85(5):807-8. doi: 10.1002/ccd.25885. PMID:25789729

Hillegass WB, Brott BC. Obesity and percutaneous coronary intervention outcomes: beware the extremes. *Catheter Cardiovasc Interv.* 2015 May;85(6):959-60. doi: 10.1002/ccd.25933. PMID:25904223

Segrest, JH, **Hillegass WB**. Renal artery stenting: patient selection post-CORAL. *Catheter Cardiovasc Interv.* 2015 Aug;86(2):310-1. doi: 10.1002/ccd.26090. PubMed PMID: 26198067.

Hillegass WB. Diabetes is not sufficient justification for Iib/IIIa use in percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2015 Sep;86(3):376-7. doi: 10.1002/ccd.26130. PubMed PMID: 26276231.

Hillegass WB. Risk-guided use of the direct thrombin inhibitor bivalirudin. *Catheter Cardiovasc Interv.* 2016 Feb 15;87(3):401-2. doi: 10.1002/ccd.26441. PubMed PMID: 26919339.

Hillegass WB, Limdi NA. Valvular Heart Disease and Acquired Type 2A von Willebrand Syndrome: The “Hemostatic” Waring Blender Syndrome. *JAMA Cardiol.* 2016; Published Online: April 6, 2016. doi:10.1001/jamacardio.2016.0182.

Hillegass WB. End of the bare metal stent era? *Catheter Cardiovasc Interv.* 2016 Jul;(88)1: 49-50. doi: 10.1002/ccd.26640. PubMed PMID:27400635 <http://www.medscape.com/viewpublication/11069>.

Hillegass WB, Bradford G. Risk-guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses. *Journal of Thoracic Disease.* 2016; 8(9) : E1034-E1040.

Sarraf M, **Hillegass WB.** Routine Invasive Evaluation in Non ST Elevation Myocardial infarction (NSTEMI-ACS): Optimizing Best. *Catheter Cardiovasc Interv.* 2016 Nov;88(5):775-776. doi: 10.1002/ccd.26824. PubMed PMID: 27865071.

Segrest JH, **Hillegass WB.** Radial Access Optimization in the Nascent Post-Adoption Era. *Catheter Cardiovasc Interv.* 2016 Dec;88(7):1044-1045. doi:10.1002/ccd.26864. PubMed PMID: 27976546.

Chatterjee A, **Hillegass WB.** Unprotected Left Main Disease and Percutaneous Intervention: A Prototype for Precision Medicine. *Catheter Cardiovasc Interv.* 2017 Jan;89(1):11-12. doi: 10.1002/ccd.26893. PubMed PMID: 28116861.

Harada S, Zhou Y, Duncan S, Armstead AR, Coshatt GM, Dillon C, Brott BC, Willig J, Alsip JA, **Hillegass WB**, Limdi NA. Precision Medicine at the University of Alabama at Birmingham: Laying the foundational processes through implementation of Genotype-Guided Antiplatelet Therapy. *Clin Pharmacol Ther.* 2017 Jan 25. doi: 10.1002/cpt.631. [Epub ahead of print] Review. PubMed PMID:28124392.

Hillegass WB. The Many Radial Access Learning Curves. *Catheter Cardiovasc Interv.* 2017 Apr;89(5):865-866. doi: 10.1002/ccd.27046. PubMed PMID: 28419790.

Boehme AK, Pamboukian SV, George JF, Beasley TM, Kirklin JK, Tallaj J, Dillon C, Levitan EB, Griffin R, McGwin G Jr, **Hillegass WB**, Limdi NA. Anticoagulation Control in Patients With Ventricular Assist Devices. *ASAIO J.* 2017 May 9. doi:10.1097/MAT.0000000000000592. [Epub ahead of print] PubMed PMID: 28492415.

Chatterjee A, **Hillegass WB.** Length and Pressure Matter: Expediting Evidence-Based Progress in Femoropopliteal Intervention *Catheter Cardiovasc Interv.* 2017 Jun 1;89(7):1257-1258. doi: 10.1002/ccd.27131. PMID:28612417

Chatterjee A, **Hillegass WB.** Individualizing dual antiplatelet therapy duration: Prediction tools, genomics, and clinical judgment. *Catheter Cardiovasc Interv.* 2017 Jul;90(1):38. doi: 10.1002/ccd.27166. PubMed PMID: 28707449.

Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, **Hillegass WB**, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramaju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2017 Oct 25. pii:S1936-8798(17)31499-1. doi: 10.1016/j.jcin.2017.07.022. [Epub ahead of print] PubMed PMID: 29102571.

Chatterjee A, **Hillegass WB.** Patient Preference: An Important Emerging Factor in Operator Access Site Selection. *Catheter Cardiovasc Interv.* *Catheter Cardiovasc Interv.* 2018 Jan 1;91(1):25-26. doi: 10.1002/ccd.27457. PubMed PMID: 29314640.

Chatterjee A, **Hillegass WB**. The promise of effective P2Y₁₂ platelet receptor pretreatment: not crushed yet. *Catheter Cardiovasc Interv*. 2018 Feb 1;91(2):251-252. doi: 10.1002/ccd.27512. PubMed PMID: 29405601.

Zoghbi GJ, Misra VK, Brott BC, Papapietro SE, Dai D, Wang TY, Klein LW, Messenger JC, **Hillegass WB**. Contemporary Percutaneous Coronary Intervention for Patients with Acute Myocardial Infarction and Left Main Culprit Lesions: A Report from the NCDR®. *Open J Cardiol Heart Dis*. 1(3). OJCHD.000513.2018.

Xie R, **Hillegass WB**. Long-term survival prospects of patients undergoing percutaneous coronary intervention: Envisioning the future. *Catheter Cardiovasc Interv*. 2018 Mar 1;91(4):696. doi: 10.1002/ccd.27560. PubMed PMID: 29532644.

b) book chapters

WB Hillegass, HL Kimbrough. Surgical utilization and second opinions. Second Thoughts on Health Care, Unger, Copeland, and Southworth, editors, NTC, Skokie, IL, 1977. Pp. 150-157.

WB Hillegass, HL Kimbrough, H Slatkin. Energy conservation and foreign oil dependence. On Establishing an Energy Policy, James J. Unger, editor. The National Textbook Company, Skokie, IL, 1978. Pp. 131-184.

WB Hillegass, EM Ohman, RM Califf. Restenosis: the clinical issues. In Topol EJ (ed): Textbook of Interventional Cardiology, 2nd ed. Philadelphia, WB Saunders 1993.

DF Fortin, JE Tchong, **WB Hillegass**, HR Phillips. Restenosis: a practical guide to prevention and management. In Roubin GS, Phillips HR, O'Neill W, Califf RM, Stack RS (eds): Interventional Cardiovascular Medicine: Principles and Practice, New York, Churchill Livingstone 1994.

RE Federici, AN Tenaglia, **WB Hillegass**, RA Harrington, EM Ohman. Prevention and management of abrupt closure. Ellis SG, Holmes DR (eds): Strategic Approaches in Coronary Intervention, Baltimore, Williams & Wilkins, 1996.

WB Hillegass, WD Jordan. Endovascular therapies for diseases of the aorta. Stack RS, Roubin GS, O'Neill WW, (eds): Interventional Cardiovascular Medicine: Principles and Practice, 2nd edition, New York, Churchill Livingstone, 2001.

GJZoghbi, **WB Hillegass**. Adjunctive Pharmacology during Percutaneous Coronary Intervention. Ragavendra R. Baliga (editor), Specialty Board Review: Cardiology, McGraw Hill, 2011. ISBN-13: 978-0071614085
ISBN-10: 0071614087

Bartolucci, AA., **Hillegass, WB**. Overview, strengths and limitations of systematic reviews and meta- analyses. Book Chapter in "Evidence-Based Practice Toward Optimizing Clinical Outcomes". Chiappelli, F., Caldeira Brant, X.M., Neagos, N., Oluwadara, O.O., Ramchandani, M.H. (Eds.) Springer-Verlag, Berlin, Heidelberg. 2010. pp 17-34 ISBN 978-3-642-05025-1

c) miscellaneous

WB Hillegass, A Hutter. The role of exercise tests after angioplasty. ACCEL Program, American College of Cardiology, side 3, Jan. 1993.

WB Hillegass. Book Review; Manual of Interventional Cardiology. Circulation 1998.

WB Hillegass, S Tatineni. Commentary: abciximab and stenting reduced death, myocardial infarction, and repeated revascularization in coronary revascularization. ACP Journal Club 2000;132(1):5.

WB Hillegass. Commentary: pentoxifylline alone or as an adjunct to compression therapy improves healing in venous leg ulcers. ACP Journal Club 2001;134(1):14.

WB Hillegass, GD Chapman. Commentary: coumarin and aspirin reduced clinical events more than aspirin alone when drugs were started before scheduled PTCA. ACP Journal Club 2001; 134(2):51.

WB Hillegass, GD Chapman. Commentary: Review: glycoprotein IIb/IIIa inhibitors reduce MI and urgent revascularization but increase bleeding in PCI. ACP Journal Club 2001; 134(3):90.

WB Hillegass, AE Epstein. Commentary: Cardiac resynchronization was effective for moderate-to-severe heart failure with intraventricular conduction delay. ACP Journal Club 2002; 135(3): 82.

WB Hillegass, AE Epstein. Commentary: Cardiac resynchronization was effective for moderate-to-severe heart failure with intraventricular conduction delay. Evidence-Based Medicine 2002; 7(6): 172.

BC Brott, WB Hillegass. Commentary: An early invasive strategy reduced death, myocardial infarction, and hospital readmissions at 2 years in unstable CAD. ACP Journal Club 2003; 139:30.

WB Hillegass, BC Brott. Commentary: An interventional strategy was better than a conservative strategy in unstable angina or non-ST-elevation myocardial infarction. ACP Journal Club 2003; 138(2):32.

WB Hillegass, BC Brott. Commentary: Use of low molecular weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. ACP Journal Club 2003; 139(3):58.

WB Hillegass. Book Review: Cardiovascular Health Care Economics. JAMA 2004;291(17):2134.

WB Hillegass, GK Alam. Commentary: High-dose atorvastatin was superior to standard-dose pravastatin for reducing death or major cardiovascular events in acute coronary syndromes. ACP Journal Club 2004; 141(2):33.

WB Hillegass, GK Alam. Commentary: High-dose atorvastatin was superior to standard-dose pravastatin for reducing death or major cardiovascular events in acute coronary syndromes. Evidence-Based Medicine 2004; 9(5):144.

WB Hillegass, BC Brott. Commentary: An invasive strategy within 24 hours of thrombolysis was better than a conservative ischemia-guided strategy for reducing death, non-fatal reinfarction, or ischemia-induced revascularization in STEMI. ACP Journal Club 2005; 142(2):38.

WB Hillegass. Commentary: PCI with bivalirudin and provisional GP IIb/IIIa inhibition is more cost-effective than heparin plus routine GP IIb/IIIa inhibition. Evidence-Based Cardiovascular Medicine 2005; 9:70-71.

R Gupta, WB Hillegass. Book Review: Atherothrombosis and Coronary Artery Disease, edited by Valentin Fuster, Eric J. Topol, and Elizabeth G. Nabel, 2nd ed, JAMA 2005;294:1555-1556.

WB Hillegass, HT McElderry. Commentary: Prophylactic implantable cardioverter-defibrillators increased life expectancy with an acceptable cost-effectiveness ratio. ACP Journal Club 2006; 144 (2):52.

A Suarez, S Rajdev, **WB Hillegass**. Commentary: Rescue angioplasty reduced cardiovascular and cerebrovascular outcomes in acute MI after failed thrombolytic therapy. ACP Journal Club 2006; 144(3):60.

A Suarez, S Rajdev, **WB Hillegass**. Commentary: Review: Evidence supporting reduced death and reinfarction by percutaneous coronary intervention after thrombolysis is inconclusive. ACP Journal Club 2006; 144(3):61.

WB Hillegass, BC Brott, Commentary: Urgent revascularization with PCI was more cost-effective than CABG in medically refractory, high-risk myocardial ischemia. ACP J Club. 2007 Mar-Apr;146(2):49.

Dorfman TA, Hillegass WB. Commentary: Aspirin was cost-effective for primary prevention of cardiovascular events in older women at moderate risk. ACP J Club. 2007 Jul-Aug;147(1):24.

BC Brott, **WB Hillegass**. Review: Late percutaneous coronary intervention after AMI improves survival more than optimal medical therapy. ACP J Club 2008; 149(1)6.

WB Hillegass, BC Brott. Commentary: Prasugrel reduces events and stent thrombosis in acute coronary syndrome patients undergoing PCI. ACP J Club 2008; 149(3):12.

WB Hillegass. Improving catheterization laboratory outcomes and safety. Joint Commission Resources. DVD. 2008.

WB Hillegass, BC Brott. Commentary: Prasugrel prevented ischemic events compared with clopidogrel in patients having PCI for STEMI. ACP J Club 2009; 150(12):JC6-10.

WB Hillegass. Review: Third-generation P2Y₁₂ inhibitors reduce mortality after PCI more than clopidogrel ACP Journal Club 2011;15 March 2011; 154(6): JC 3-6.

BC Brott, **WB Hillegass**. Commentary: 24- and 6-month dual antiplatelet therapy after coronary stenting did not differ for clinical outcomes Ann Intern Med. 21 August 2012;157(4):JC2-9

d) published abstracts

WB Hillegass, ANA Tosteson, L Goldman, CS Landefeld, and T Lee. Optimal management strategies for patient subsets with suspected pulmonary embolism: a decision analytic approach (Abstr). Clinical Research 1988; 36:713A.

WB Hillegass, A Jiminez, DA Brezinski, GH Tofler, AI Schafer, GH Williams, and JE Muller. The effect of postural change on platelet aggregability (Abstr). Soma Weis Assembly, Harvard Medical School, April 21, 1988, Boston, MA.

WB Hillegass, DB Mark, JG Jollis, EM Ohman, DB Pryor. Streptokinase therapy for acute myocardial infarction is cost-effective in the elderly (Abstr). Circulation 1992;86:I-40.

WB Hillegass, M Ancukiewicz, JR Bengtson, ER Delong, GC Timmis, FA McGrew, DB Pryor, for the GRASP Investigators. Does follow-up exercise testing predict restenosis after successful angioplasty? (Abstr) Circulation 1992;86:I-137.

WB Hillegass, JR Bengtson, M Ancukiewicz, ER Delong, GC Timmis, FA McGrew, DB Pryor, for the GRASP Investigators. Pre-discharge exercise testing does not predict clinical events or restenosis after successful angioplasty (Abstr). Circulation 1992;86:I-137.

WB Hillegass, JG Jollis, CB Granger, RM Califf, DB Mark. How many lives does a new more potent thrombolytic agent have to save to justify additional intracranial hemorrhages? (Abstr) Clinical Research 1993;41:122A.

ED Peterson, DM Unks, MB Higginbotham, DB Mark, **WB Hillegass**. Nonischemic dilated cardiomyopathy: when is prophylactic anticoagulation worth the risk? (Abstr) Clinical Research 1993;41:217A.

WB Hillegass, Timmis GC, McGrew FA, Bengtson JR, Ancukiewicz M, DeLong ER, Pryor DA, GRASP Investigators. Incomplete revascularization at angioplasty limits the usefulness of follow-up exercise testing in predicting restenosis (Abstr). *Circulation* 1993; 88: I-64.

WB Hillegass, ED Peterson, JG Jollis. What cost of therapies to reduce restenosis is justified? (Abstr) *Circulation* 1993; 88: I-145.

WB Hillegass, ANA Tosteson, L Goldman, CS Landefeld, and TH Lee. The optimal management of patients with suspected pulmonary embolism: a decision analysis (with lower extremity noninvasive testing) (Abstr). *JACC* 1993;21:219A.

WB Hillegass, CR Narins, BC Brott, EB Haura, HR Phillips, RS Stack, RM Califf. Activated clotting time predicts bleeding complications from angioplasty (Abstr). *JACC* 94: 184A.

WB Hillegass, BC Brott, CR Narins, EB Haura, HR Phillips, RS Stack, RM Califf. Predictors of blood loss and bleeding complications after angioplasty (Abstr). *JACC* 94: 69A.

CR Narins, **WB Hillegass**, CL Nelson, RA Harrington, HR Phillips, RS Stack, RM Califf. Activated clotting time predicts abrupt closure risk during angioplasty (Abstr). *JACC* 94: 470A.

BC Brott, SC Culp, JP Zidar, M Labinaz, **WB Hillegass**, MH Sketch, HR Phillips, RS Stack. Thermal/perfusion balloon angioplasty: lower temperature efficacy in an *in vivo* atherosclerotic rabbit model (Abstr). *JACC* 94: 187A.

WB Hillegass, BC Brott, EM Ohman. Outcomes after percutaneous transluminal coronary angioplasty: a physician derived composite index (Abstr). *Cath. Card. Diag.* 94;32:93.

WB Hillegass, EM Ohman, MA O'Hanesian, RA Harrington, DP Faxon, DF Fortin, SG Ellis, RS Stack, DR Holmes, RM Califf. The effect of preprocedural intracoronary thrombus on patient outcome after percutaneous coronary intervention (Abstr). *JACC* 95: 94A.

WB Hillegass, BC Brott, EB Haura, RA Harrington, HR Phillips, RS Stack, RM Califf. Patient-specific heparin dosing during angioplasty (Abstr). *JACC* 95: 391A.

AR Newman, DL Raco, **WB Hillegass**. Comparative cost-effectiveness of the IIb/IIIa glycoprotein blockade agents in percutaneous coronary intervention (Abstr). *JACC* 99: 295A.

MA Todd, AR Newman, DL Raco, **WB Hillegass**. A new composite outcome measure for coronary intervention (Abstr). *JACC* 99: 286A.

WB Hillegass, NA Dean, L Liao, RG Rhinehart, PR Myers. Treatment of no-reflow with the intracoronary administration of the nitric oxide donor nitroprusside: initial human clinical experience. *Circulation* 99:100;4123.

WB Hillegass, NA Dean, L Liao, GD Chapman, VK Misra, DL Raco, BC Brott, PR Myers. Treatment of no-reflow with the intracoronary administration of the nitric oxide donor nitroprusside: initial human clinical experience. *Amer J of Cardiol* 99:84;5P.

A Tenaglia, FO Mendelsohn, RD Anderson, K Rocha-Singh, **WB Hillegass**, JJ Crowley, R Guzman, T Moon, MJ Whitehouse, RJ Lederman, BH Annex. Diabetics respond to fibroblast growth factor-2. Findings in the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial. *Circulation* 2001;104:II-262.

WS Abo-Auda, GJ Zoghbi, AD Patel, **WB Hillegass**. Interventional strategy in reducing cardiac enzyme elevations following percutaneous interventions of saphenous vein grafts. *Amer J of Cardiol* 2002; 90(6): 105H.

WS Abo-Auda, GJ Zoghbi, AD Patel, **WB Hillegass**. Thromboatherectomy during percutaneous saphenous vein graft intervention improves graft patency. *Amer J of Cardiol* 2002; 90(6):106H.

JG Canto, **WB Hillegass**, C Fincher, R Mallick,. Routine use of ramipril is cost-effective after percutaneous coronary intervention. *Journal of the American College of Cardiology* 2003; 41(6):524.

SK Koshy, S Ahmed, W McMahon, WR Lau, **WB Hillegass**, JE Knoblauch, VK Misra. Utility of intracardiac echocardiography in moderate to high risk percutaneous transvenous mitral balloon commissurotomy. *Catheterization and Cardiovascular Interventions* 2005; 65(1): 93.

D Mehta, R Dhall, D Coupland , R Soto, **WB Hillegass**, VK Misra. Percutaneous intervention for intracranial carotid artery disease. *Circulation* 2005;112(17): II-369.

D Mehta, R Dhall, D Coupland , R Soto, **WB Hillegass**, VK Misra. Percutaneous interventions of basilar artery stenoses. *Circulation* 2005;112(17): II-369.

WB Hillegass, SE Papapietro, BC Brott, PR Myers, GD Chapman, KA Modi, VK Misra. Interventional operator does not predict hospital cost after clinical and angiographic case-mix correction. *JACC* 2006;47:7B.

WB Hillegass, GD Chapman, PR Myers, KA Modi, SE Papapietro, VK Misra, BC Brott. Predictors of hospital cost in percutaneous coronary intervention. *JACC* 2006; 47:8B.

D Mehta, R Dhall, R Gupta, R Soto, **WB Hillegass**, VK Misra. Percutaneous interventions of vertebral artery stenoses. *JACC* 2006;47:35B.

WB Hillegass, VK Misra, BC Brott. Case-mix explains cost variance among percutaneous coronary interventional operators. *Catheterization and Cardiovascular Interventions* 2006;67(5):736-737.

MW Mayhew, RE Ershadi, S Mirza, GZ Zoghbi, BC Brott, **WB Hillegass**. Hyperglycemia predicts contrast-induced renal dysfunction. *Catheterization and Cardiovascular Interventions* 2006;67(5):737.

RE Ershadi, MW Mayhew, S Mirza, JE Knobloch, VJ Misra, **WB Hillegass**. Prophylactic administration of N-acetylcysteine does not prevent contrast-induced nephropathy in patients with chronic kidney disease undergoing angiography in routine practice. *Catheterization and Cardiovascular Interventions* 2006;67(5):790.

GJ Zoghbi, MK Goyal, FG Hage, NJ Patel, BC Brott, VK Misra, PR Myers, **WB Hillegass**. Prophylactic nitroprusside administration in saphenous vein graft intervention reduces the risk of periprocedural myonecrosis. *Catheterization and Cardiovascular Interventions* 2006;67(5):800.

S Rajdev, A Suarez, MK Goyal, **WB Hillegass**, VK Misra. Application of intracardiac echocardiography in high risk percutaneous balloon mitral valvuloplasty and its comparison with transthoracic echocardiography. Accepted at Pediatric & Adult Interventional Therapies for Congenital & Valvular Heart Disease 9/11/2006, Las Vegas, NV.

GJ Zoghbi, MK Goyal, FG Hage, BC Brott, VK Misra, PR Myers, **WB Hillegass**. Prophylactic sodium nitroprusside administration in saphenous vein graft intervention reduces the frequency and magnitude of post-procedural cardiac marker elevation. (Abstract) *Circulation* 2006;114(18);Supplement II-786, abstract 3681..

WB Hillegass, BC Brott, RE Ershadi, MW Mayhew, SE Papapietro, GD Chapman, PR Myers, VK Misra. Preprocedural anemia is a significant predictor of hospital cost in percutaneous coronary intervention. Moderated Poster Presentation - AHA Scientific Sessions, November 2006. *Circulation*, Volume 114, Number 18, October 31, 2006, (Supplement), II-862, abstract 4011.

RE Ershadi, MW Mayhew, S Mirza, GJ Zoghbi, AK Kelly, VK Misra, BC Brott, **WB Hillegass**. Exacerbation or development of hyperglycemia predicts peri-procedural nephropathy. (Abstract) *Circulation* 2006;114(18);Supplement II-872.

WB Hillegass, MJ Lysterly, NJ Patel, GJ Zoghbi, VK Misra, BC Brott, Frequency and predictors of post-procedural myonecrosis in saphenous vein graft intervention in the stent era: a meta-regression. (Abstract) *Circulation* 2006;114(18);Supplement II-733.

N Beohar, CJ Davidson, **W Hillegass**, E Massaro, M Hlatky, M Krauland, M Korytkowski, K Melsop, M Brooks for BARI 2D Investigators. Impact of asymptomatic and symptomatic end organ effects of diabetes mellitus on quality of life in the bypass angioplasty revascularization investigation of type 2 diabetes (BARI 2D). (Abstract) *Circulation* 2006;114(18);Supplement II-845, abstract 3928.

S Rajdev, A Suarez, KA Modi, BC Brott, RM Aqel, **WB Hillegass**, VK Misra. "Cone Crush", A Variant of Modified T-Stenting Technique for Coronary Bifurcation Lesions: Bench Testing, Clinical Feasibility and In-hospital Outcomes. (accepted ACC 2007)

G Koerbel, M Korytkowski, M Brooks, SC Chung, J Escobedo, **W Hillegass**, E Massaro, W Rogers. The contribution of hypoglycemic therapy and gender on quality of life measures in patients with type two diabetes and coronary artery disease in BARI 2D. (accepted ADA 2007)

Mehta D, Dhall R, Gupta R, Soto R, **Hillegass WB**, Misra VK. Outcomes and long-term survival after percutaneous vertebral artery intervention. *Cath & Cardiovascular Interventions* 2007;69(6): abstract O-3, page S1.

Hillegass WB, Mayhew MW, Ershadi RE, Myers PR, Papapietro SE, Misra VK, Brott BC. Periprocedural hyperglycemia is a powerful independent predictor of hospital cost in patients undergoing PCI. *Catheterization and Cardiovascular Interventions* 2007;69(6):S77, abstractD4, page S77.

Suarez A, Zoghbi GJ, Rajdev S, Brott BC, Aqel R, **Hillegass WB**, Misra VK. In-hospital outcomes of rotational atherectomy in a large cohort of patients with depressed left ventricular function. (Abstract) *Catheter Cardiovasc Interven* 2007;69(6): abstract A28, page S21.

Suarez A, Mayhew MW, Ershadi RE, Mirza S, Knobloch JE, Brott BC, Misra VK, **Hillegass, WB**. Postprocedure administration of N-acetyl cysteine does not prevent contrast-induced nephropathy in patients with chronic kidney disease undergoing angiography in routine practice. *Catheterization and Cardiovascular Interventions* 2007;69(6): abstractB1, page S35.

Suarez A, Mehta D, **Hillegass WB**, Misra VK. Percutaneous intervention of isolated common carotid artery disease. *Cath & Cardiovascular Interventions* 2007;69(6): abstract A30, page S22.

WB Hillegass, NJ Patel, MJ Lysterly SE Papapietro, VK Misra, BC Brott. Frequency and predictors of post-procedural myonecrosis in saphenous vein graft intervention in the stent and distal protection era: a meta-regression. *Catheterization and Cardiovascular Interventions* 2007;69(6): abstract B49, page S52.

Todd A. Dorfman, Brigitta C. Brott, Reza E. Ershadi, Vijay K. Misra, and **WB Hillegass** Outcomes of Stenting for Renovascular Disease: A Meta-Regression of the Published Experience (abstract). *Circulation* 2008;118: 18 (S1079).

RH. Mehta, FS Ou, ED Peterson, RE Shaw, **WB Hillegass**, JS Rumsfeld, MT Roe, On Behalf of the American College of Cardiology-National Cardiovascular Database Registry Investigators. Clinical Significance of Thrombolysis In Myocardial Infarction Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. *Circulation* 2008; 118: 18 (S633).

Brott BC, **Hillegass WB**, Misra VK, Papapietro SE, Zoghbi GJ. Depressed left ventricular function carries a worse in-hospital outcome in patients undergoing rotational atherectomy. *Catheterization and Cardiovascular Interventions* 2009;73(7): abstractA33, page S21.

Hillegass WB, Brott BC. Primary prevention in diabetics: aspirin is insufficient. *Circulation* 2009; 120:S473. Presented AHA 2009.

ARM Sridhar, VK Misra, SM Taylor, AA Bartolucci, **WB Hillegass**. Expected outcomes of superficial femoral artery (sfa) endovascular interventions: a meta-analysis. Presented AHA 2009.

MM Brooks, J Escobedo, SC Chung, **WB Hillegass**, E Massaro, KA Melsop, T Helmy, R McBane, P Hyde, MA Hlatky. Quality of life results in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Presented at late breaking clinical trials at AHA 2009.

GJ Zoghbi, VK Misra, BC Brott, SE Papapietro, D Dai, FS Ou, TY Wang, LW Klein, JC Messenger, **WB Hillegass**. Myocardial Infarction with Left Main Culprit Lesion PCI in Prior CABG Patients: A Report from the National Cardiovascular Data Registry Presented ACC 2010.

WB Hillegass. GJ Zoghbi, VK Misra, BC Brott, SE Papapietro, D Dai, FS Ou, TY Wang, LW Klein, JC Messenger, Non ST Elevation Myocardial Infarction and Left Main Culprit lesions: Contemporary Percutaneous Coronary Interventions Outcomes. Presented ACC 2010.

Hillegass, WB, Dai, D, Patel, M, Rao SV, Messenger, JA, Anstrom, KA, Honeycutt, E, Peterson, E, Douglas PA. Acute and Long-Term Outcomes in Older Diabetic Patients Receiving a Coronary Stent: Contemporary Results in 405,679 Patients. Presentation at ACC 2011.

WB Hillegass, GJ Zoghbi, BC Brott, ML Kilgore, GD Chapman, VK Misra, Cost-Effectiveness of New Oral Antiplatelet Agents and Testing Strategies during Early Invasive Management of Acute Coronary Syndrome Patients. Presented AHA 2011.

ARM Sridhar, S Parasa, GS Panjra, TA Dorfman, **WB Hillegass**. Trends in Utilization and Costs of Left Ventricular Assist Device Therapy for Advanced Heart Failure in US - Results From the Nationwide Inpatient Sample 2005-2008, Presented AHA 2011.

J Zhang, L Chen, E Delzell, P Muntner, **WB Hillegass**, M Safford, JR Curtis The association between inflammatory markers and hyperlipidemia and the risk of myocardial infarction in patients with rheumatoid arthritis 2012 ACR/ARHP Annual Meeting accepted for presentation.

Hess CN, Peterson ED, Dai D, Neely M, Piana R, **Hillegass WB**, Kutcher M, Messenger J, Pancholy S, Rao S. Relationship between transradial PCI experience and procedural metrics. *JACC* 2013;61(10)E1852. (abstract, oral presentation American College of Cardiology Annual Scientific session, San Francisco, CA)

Hillegass WB, Brott BC, Zoghbi GJ, Chapman GC, Misra VK, Kilgore ML. Time-Dependent Cost-Effectiveness of New Oral Antiplatelet Agents for Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. Oral abstract, National Research Service Administration Meeting, Baltimore MD, 6/2013.

Hillegass WB, Brott BC, Cutter GR. Is prasugrel superior to optimally dosed clopidogrel? *Catheter Cardiovasc Interv.* 2016 May 1;87(Supplement 2):114-115.